\
&
Contact us
\
&
Contact us
Science with and for Society (SwafS) will help build effective cooperation between science and society, to recruit new talent for science and to pair scientific excellence with social awareness and responsibility.
Science with and for Society will be instrumental in addressing the European societal challenges tackled by Horizon 2020, building capacities and developing innovative ways of connecting science to society. It will make science more attractive (notably to young people), raise the appetite of society for innovation, and open up further research and innovation activities. It allows all societal actors (researchers, citizens, policy makers, business, third sector organisations etc.) to work together during the whole research and innovation process in order to better align both the process and its outcomes with the values, needs and expectations of European society. This approach to research and innovation is termed Responsible Research and Innovation (RRI).
The Science with and for Society (SwafS) work programme 2018-2020 shall focus on five calls for proposals in which proposals are invited against specific topics:
margot.beereboom@fwo.be
+32 2 550 15 76
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
